Cargando…

Cisplatin-Induced Nephrotoxicity; Protective Supplements and Gender Differences

Cisplatin (CDDP) has been widely used as a chemotherapeutic agent for solid tumors. The most common side effect of CDDP is nephrotoxicity, and many efforts have been made in the laboratory and the clinic to employ candidate adjuvants to CDDP to minimize this adverse influence. Many synthetic and her...

Descripción completa

Detalles Bibliográficos
Autores principales: Nematbakhsh, Mehdi, Pezeshki, Zahra, Jazi, Fatemeh Eshraghi, Mazaheri, Bahar, Moeini, Maryam, Safari, Tahereh, Azarkish, Fariba, Moslemi, Fatemeh, Maleki, Maryam, Rezaei, Alireza, Saberi, Shadan, Dehghani, Aghdas, Malek, Maryam, Mansouri, Azam, Ghasemi, Marzieh, Zeinali, Farzaneh, Zamani, Zohreh, Navidi, Mitra, Jilanchi, Sima, Shirdavani, Soheyla, Ashrafi, Farzaneh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454720/
https://www.ncbi.nlm.nih.gov/pubmed/28345324
http://dx.doi.org/10.22034/APJCP.2017.18.2.295
_version_ 1783240887814324224
author Nematbakhsh, Mehdi
Pezeshki, Zahra
Jazi, Fatemeh Eshraghi
Mazaheri, Bahar
Moeini, Maryam
Safari, Tahereh
Azarkish, Fariba
Moslemi, Fatemeh
Maleki, Maryam
Rezaei, Alireza
Saberi, Shadan
Dehghani, Aghdas
Malek, Maryam
Mansouri, Azam
Ghasemi, Marzieh
Zeinali, Farzaneh
Zamani, Zohreh
Navidi, Mitra
Jilanchi, Sima
Shirdavani, Soheyla
Ashrafi, Farzaneh
author_facet Nematbakhsh, Mehdi
Pezeshki, Zahra
Jazi, Fatemeh Eshraghi
Mazaheri, Bahar
Moeini, Maryam
Safari, Tahereh
Azarkish, Fariba
Moslemi, Fatemeh
Maleki, Maryam
Rezaei, Alireza
Saberi, Shadan
Dehghani, Aghdas
Malek, Maryam
Mansouri, Azam
Ghasemi, Marzieh
Zeinali, Farzaneh
Zamani, Zohreh
Navidi, Mitra
Jilanchi, Sima
Shirdavani, Soheyla
Ashrafi, Farzaneh
author_sort Nematbakhsh, Mehdi
collection PubMed
description Cisplatin (CDDP) has been widely used as a chemotherapeutic agent for solid tumors. The most common side effect of CDDP is nephrotoxicity, and many efforts have been made in the laboratory and the clinic to employ candidate adjuvants to CDDP to minimize this adverse influence. Many synthetic and herbal antioxidants as well as trace elements have been investigated for this purpose in recent years and a variety of positive and negative results have been yielded. However, no definitive supplement has so far been proposed to prevent CDDP-induced nephrotoxicity; however, this condition is gender related and the sex hormone estrogen may protect the kidney against CDDP damage. In this review, the results of research related to the effect of different synthetic and herbal antioxidants supplements are presented and discussed with suggestions included for future work.
format Online
Article
Text
id pubmed-5454720
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-54547202017-08-28 Cisplatin-Induced Nephrotoxicity; Protective Supplements and Gender Differences Nematbakhsh, Mehdi Pezeshki, Zahra Jazi, Fatemeh Eshraghi Mazaheri, Bahar Moeini, Maryam Safari, Tahereh Azarkish, Fariba Moslemi, Fatemeh Maleki, Maryam Rezaei, Alireza Saberi, Shadan Dehghani, Aghdas Malek, Maryam Mansouri, Azam Ghasemi, Marzieh Zeinali, Farzaneh Zamani, Zohreh Navidi, Mitra Jilanchi, Sima Shirdavani, Soheyla Ashrafi, Farzaneh Asian Pac J Cancer Prev Review Cisplatin (CDDP) has been widely used as a chemotherapeutic agent for solid tumors. The most common side effect of CDDP is nephrotoxicity, and many efforts have been made in the laboratory and the clinic to employ candidate adjuvants to CDDP to minimize this adverse influence. Many synthetic and herbal antioxidants as well as trace elements have been investigated for this purpose in recent years and a variety of positive and negative results have been yielded. However, no definitive supplement has so far been proposed to prevent CDDP-induced nephrotoxicity; however, this condition is gender related and the sex hormone estrogen may protect the kidney against CDDP damage. In this review, the results of research related to the effect of different synthetic and herbal antioxidants supplements are presented and discussed with suggestions included for future work. West Asia Organization for Cancer Prevention 2017 /pmc/articles/PMC5454720/ /pubmed/28345324 http://dx.doi.org/10.22034/APJCP.2017.18.2.295 Text en Copyright: © Asian Pacific Journal of Cancer Prevention http://creativecommons.org/licenses/BY-SA/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
spellingShingle Review
Nematbakhsh, Mehdi
Pezeshki, Zahra
Jazi, Fatemeh Eshraghi
Mazaheri, Bahar
Moeini, Maryam
Safari, Tahereh
Azarkish, Fariba
Moslemi, Fatemeh
Maleki, Maryam
Rezaei, Alireza
Saberi, Shadan
Dehghani, Aghdas
Malek, Maryam
Mansouri, Azam
Ghasemi, Marzieh
Zeinali, Farzaneh
Zamani, Zohreh
Navidi, Mitra
Jilanchi, Sima
Shirdavani, Soheyla
Ashrafi, Farzaneh
Cisplatin-Induced Nephrotoxicity; Protective Supplements and Gender Differences
title Cisplatin-Induced Nephrotoxicity; Protective Supplements and Gender Differences
title_full Cisplatin-Induced Nephrotoxicity; Protective Supplements and Gender Differences
title_fullStr Cisplatin-Induced Nephrotoxicity; Protective Supplements and Gender Differences
title_full_unstemmed Cisplatin-Induced Nephrotoxicity; Protective Supplements and Gender Differences
title_short Cisplatin-Induced Nephrotoxicity; Protective Supplements and Gender Differences
title_sort cisplatin-induced nephrotoxicity; protective supplements and gender differences
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454720/
https://www.ncbi.nlm.nih.gov/pubmed/28345324
http://dx.doi.org/10.22034/APJCP.2017.18.2.295
work_keys_str_mv AT nematbakhshmehdi cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences
AT pezeshkizahra cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences
AT jazifatemeheshraghi cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences
AT mazaheribahar cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences
AT moeinimaryam cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences
AT safaritahereh cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences
AT azarkishfariba cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences
AT moslemifatemeh cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences
AT malekimaryam cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences
AT rezaeialireza cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences
AT saberishadan cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences
AT dehghaniaghdas cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences
AT malekmaryam cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences
AT mansouriazam cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences
AT ghasemimarzieh cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences
AT zeinalifarzaneh cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences
AT zamanizohreh cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences
AT navidimitra cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences
AT jilanchisima cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences
AT shirdavanisoheyla cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences
AT ashrafifarzaneh cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences